Authors
Rolf D Issels, Lars H Lindner, Jaap Verweij, Rüdiger Wessalowski, Peter Reichardt, Peter Wust, Pirus Ghadjar, Peter Hohenberger, Martin Angele, Christoph Salat, Zeljko Vujaskovic, Soeren Daugaard, Olav Mella, Ulrich Mansmann, Hans Roland Dürr, Thomas Knösel, Sultan Abdel-Rahman, Michael Schmidt, Wolfgang Hiddemann, Karl-Walter Jauch, Claus Belka, Alessandro Gronchi
Publication date
2018/4/1
Journal
JAMA oncology
Volume
4
Issue
4
Pages
483-492
Publisher
American Medical Association
Description
Importance
Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment. Preoperative anthracycline plus ifosfamide chemotherapy improves outcome in common histological subtypes.
Objective
To analyze whether the previously reported improvement in local progression-free survival by adding regional hyperthermia to neoadjuvant chemotherapy translates into improved survival.
Design, Setting, and Participants
Open-label, phase 3 randomized clinical trial to evaluate the efficacy and toxic effects of neoadjuvant chemotherapy plus regional hyperthermia. Adult patients (age ≥18 years) with localized soft tissue sarcoma (tumor ≥5 cm, French Federation Nationale des Centers de Lutte Contre le Cancer [FNCLCC] grade 2 or 3, deep) were accrued across 9 centers (6, Germany; 1, Norway; 1, Austria; 1, United States) from July 1997 to November 2006. Follow …
Scholar articles
RD Issels, LH Lindner, J Verweij, R Wessalowski… - JAMA oncology, 2018